anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Cosmetic use of an active ingredient (I) from Lens culinarisor Lens esculentain a cosmetic composition to prevent or mitigate the unsightly aspect of dilated pores on the skin, is claimed. Independent claims are included for: (1) (I) obtained from Lens culinarisor Lens esculenta, having carbohydrate content of &gt;= 16%; (2) a preparation of (I) comprising at least one step of solubilization of grains of Lens culinarisor Lens esculentain aqueous medium and at least one enzymatic hydrolysis; (3) a cosmetic composition for topical application on the skin to mitigate the unsightly aspect of dilated pores, comprising 0.1-20 wt.% of (I) having carbohydrate (16-50%); (4) a cosmetic process for caring of the human skin, to mitigate the unsightly large pores, reduce shine and refine the skin texture, comprising topical application of a composition containing (I) derived from Lens culinarison the skin. ACTIVITY : Dermatological. MECHANISM OF ACTION : Transglutaminase-1 expression stimulator; Involucrin expression stimulator; Collagen I expression stimulator. The ability of (I) (from Lens culinaris(0.5%)) to stimulate collagen I expression was tested in normal human fibroblast by measuring the expression of mRNA. The result showed that the percentage of mRNA was 200.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an effective anti-HCV treatment.  &lt;P&gt;SOLUTION: The compound of formula (I), its pharmaceutically acceptable salt, or their mixture inhibits serine protease activity, especially, inhibits the activity of hepatitis C virus NS3-NS4A protease. Thereby, they act as inhibiting the life circle of the hepatitis C virus, and are useful as anti-viral agents. Further a pharmaceutically acceptable composition containing the compound is provided, and it is used in any of exovivo uses or administration for a patient suffering from HCV infection. The process for preparing the compound is also provided. Also, the method for treating the HCV infection in the patients is provided by administering a pharmaceutical composition containing the compound.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Method of treating sores comprises applying to sore waferlike carrier including active ingredients for treatment of sore, the carrier in contact with the sore breaking down to release active ingredients. Carrier including active ingredients is also claimed. Examples of active ingredients include lignocaine hydrochloride, local anaesthetic and cetyl pyridinium chloride. Used e.g. for treating mouth ulcers. &lt;IMAGE&gt;
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a water-dispersible plant sterol preparation capable of stably and uniformly dispersing a plant sterol into water or a water-soluble component-containing aqueous solution, an oil and fat-containing water-dispersible plant sterol preparation, a plant sterol-dispersing aqueous solution, a plant sterol-containing oil-in-water type emulsified material and a plant sterol-containing food and beverage.  &lt;P&gt;SOLUTION: The water-dispersible plant sterol preparation comprises 0.1-30 mass% plant sterol and 69-98.9 mass% one or more kinds of polyglycerol fatty acid esters as emulsifying agents. In the water-dispersible plant sterol preparation, HLB value of the emulsifying agents in whole system of the water-dispersible plant sterol preparation is 7-13. The oil and fat-containing water-dispersible plant sterol preparation comprises 0.1-30 mass% plant sterol, 69-98.9 mass% one or more kinds of polyglycerol fatty acid esters as emulsifying agents and 0.01-20 mass% oil and fat. In the oil and fat-containing water-dispersible plant sterol preparation, HLB value in whole system of the oil and fat-containing water-dispersible plant sterol preparation is 7-13.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a tumor suppressor gene useful for diagnosing and treating cancers.  &lt;P&gt;SOLUTION: A specific region of chromosome 10 (10q23.3) has been implicated to contain a tumor suppressor gene and a corresponding coding region of the gene represents a new 47 kD protein. A domain of the product has an exact match to a conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses have demonstrated that a number of exons of the gene are deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of the gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of deletions in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to the tumor suppressor (designated as TS10q23.3) are also disclosed.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The invention discloses a drug, and especially a traditional Chinese medicine composition for treating dysmenorrheal caused by qi stagnation and blood stasis. The traditional Chinese medicine composition is characterized by being composed of the following components: 6 to 9 parts of radix bupleuri, 10 to 15 parts of white peony root, 10 to 20 parts of Chinese angelica, 6 to 12 parts of ligusticum wallichii, 10 to 15 parts of corydalis tuber, 10 to 15 parts of peach seed, 10 to 20 parts of safflower, 6 to 9 parts of flying squirrel feces, 10 to 20 parts of bitter orange, 10 to 15 parts of lindera aggregata, 10 to 15 parts of cyperus rotundus, 10 to 15 parts of tree peony bark, 10 to 15 parts of cowherb seed, 6 to 10 parts of evodia, 10 to 15 parts of processed pinellia tuber, 6 to 10 parts of fresh ginger, 0.3 to 1 part of dragon&#39;s blood, and 3 to 6 parts of licorice. The traditional Chinese medicine composition relieves the symptoms by regulating qi flowing to remove stasis and thus treats the dysmenorrheal. The curative effect is prominent, and the life quality of patients is greatly improved. The provided traditional Chinese medicine composition has the advantages of good curative effect, rapid effect, and no side effect. The effective rate can reach 98.6%.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an excellent PPARγ expression regulator containing a factor directly regulating the expression of the PPARγ, to provide excellent fat differentiation regulator, lipid metabolism regulator, osteoclast function regulator and inflammation regulator, capable of regulating the differentiation of a fat cell, the lipid metabolism, the osteoclast function, and the inflammation action by inhibiting the factor, and to provide a method for screening the PPARγ expression regulator.  &lt;P&gt;SOLUTION: The PPARγ promoter sequence includes a base sequence comprising a specific sequence. The excellent PPARγ expression regulator can directly regulate the PPARγ. The excellent fat differentiation regulator, lipid metabolism regulator, osteoclast function regulator and inflammation regulator exhibit the activity thereof through the inhibition of DBP, TEF, HLF, E4BP4 or the like. The efficient screening method for the PPARγ expression regulator is also provided.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention relates to multi-stable valves and methods for their use. The multi-stable valves may include a movable physical stop and a position arm. The physical stop may be placed in the path of the arm effectively locking the valve in at least one position upon deactivation of the valve&#39;s motivating forces. The valve may be, for example, a micro valve or a microelectromechanical device. Such a valve may be used in implantable drug infusion applications and other applications having limitations on available energy. In one exemplary embodiment, the valve comprises a membrane separating two channels. The membrane may be lifted by activation of a piezo material, opening the channels for fluid flow. A physical stop may be moved into place and the piezo material deactivated, bringing to rest the arm on the physical stop. In this manner, the valve is stabilized in the open position without requiring continuous supply of energy.
PURPOSE: To decrease lipid level in poultry and to increase the lean/fat ratio by compounding a specified compd. and a salt of this compd. and an org. or inorg. base, the salt which is allowed from viewpoints of medical care, into a feed for poultry. CONSTITUTION: This feed for poultry contains (A) a compd. expressed by the formula and (B) an effective amt. of an agent to prevent production of lipid which is selected from salts allowable for medical care and salts of the compd. (A) and an org. or inorg. base. The compd. expressed by the formula is cestan, bellini, plant, etc. As for the agent to prevent production of lipid, tolrestat, sodium tolretstat, tetramethylammonium tolretstat, N-(6-methoxy-5- heptafluoropropyl-1-naphthoyl, etc., can be used. Especially, tolrestat is preferable. The amt. of the agent to prevent production of lipid in the feed is generally about &gt;=1ppm, and preferably 5 to 50ppm.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for controlling dense fluid treatment processes in order to improve the efficiency of such processes.  &lt;P&gt;SOLUTION: A method for improved control of temperature, pressure and density profiles within a pressure vessel for dense fluid treatment processes are provided. The method comprises at least one pressurization step in which the pressure in the vessel is increased and at least one depressurization step in which the pressure in the vessel is decreased. The method further comprises recycling at least a part of the fluid in at least part time of the method. The method further comprises a holding step in which the pressure in the vessel is substantially constant. The method further comprises the step of controlling the temperature of the fluid in a recirculation loop. The heat can be added to and/or extracted from the fluid in the recirculation loop. The method can control temperature, pressure and/or density profiles within the vessel.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a swallowing auxiliary for medicines, which improves swallowing of various medicines, is convenient, can be an alternative to ordinary drinking water, and does not inhibit the effects of the medicines, and moreover a novel swallowing auxiliary which can be widely applied regardless of various kinds of medicines or various kinds of dosage forms and can further be applied to healthy food products and materials thereof.  &lt;P&gt;SOLUTION: This swallowing auxiliary is obtained by using granular jelly and the granular jelly can be manufactured by the following method (A) or (B). The method (A) comprises pushing out gelled jelly, obtained by gelling a gelling agent in the presence or in the absence of a coagulant, through a pore or a net, or cutting the gelled jelly. The method (B) comprises gelling a gelling agent by pouring or dripping it into a coagulant solution. Jelly in the granular form gives remarkable effects that operations of putting a medicine thereinto or mixing a medicine therewith are carried out more smoothly and that a medicine is taken into the mouth more easily and swallowed more easily compared with the case of jelly which is not in the form of a granule though having the same formulation. The swallowing auxiliary can be applied not only to medicines but also to healthy food products and materials thereof.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
A method for reviewing sequencing data for identifying microorganisms in a sample is provided. A request to display an analysis of a result set obtained from sequencing nucleic acids from the sample is received. The result set includes sequencing statistics, nucleotide sequences mapped against microorganism reference sequences, and mapping statistics for the mapping of nucleotide sequences to each respective reference sequence. A first customizable diagnostic template is applied to the result set. The customizable diagnostic template specifies a subset of sequencing statistics, a subset of microorganisms, and a subset of mapping statistics. A customizable user interface is displayed comprising a. review&#39; status, a. first affordance for updating the review&#39; status, a summary of the subset of sequencing statistics, a summary of the subset of mapping statistics for each microorganism satisfying a minimum mapping threshold, and a second affordance for applying a second customizable diagnostic template to the result set.
The invention discloses a traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular plaque blockage diseases and a preparation method thereof, belonging to the technical field of traditional Chinese medicines. According to the records of &#34;practical Chinese medicine dictionary&#34;: the medicinal materials of ginseng, peony, chinese taxillus twig, dioscorea nipponica makino, trichosanthes kirilowii maxim, corydalis tuber, angelica, safflower and saffron have the functions of promoting blood circulation, removing blood stasis, enriching and nourishing blood, expanding blood vessels of coronary arteries of heart, increasing nutrient blood flow, promoting substance metabolism in blood and heart pumping blood, and the formula can strengthen the efficacy by combining the components. The medicines such as pubescent holly root, kudzuvine root, buckeye seed, ginkgo leaf, salvia miltiorrhiza and pseudo-ginseng expand cerebral arterial blood vessels, promote nutrient blood flow in cerebral vessels and promote the metabolism of nutrient substances in blood. The two medicinal materials are combined and the prescription is combined, so that the potency of the medicine is improved and enhanced unprecedentedly. The preparation is suitable for treating diseases caused by cardiovascular and cerebrovascular plaque blockage. The preparation has short treatment time and rapid onset of drug action. And the preparation can help patients avoid heart bypass and heart stent operation after being taken, thereby saving medical resources.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an enteric capsule whose capsular base as such is formed of an enteric film without coating the surface of the capsule with an enteric film and a method for manufacturing the same.  &lt;P&gt;SOLUTION: The enteric capsule has a capsule-forming film which contains hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), and gellan gum and the ratio of the HPMC is more than 45 to less than 80 pts.wt. and the ratio of the HPC is more than 20 to less than 55 pts.wt. per 100 pts.wt. total amount of the HPMC and the HPC, and the ratio of the gellan gum is more than 0 to less than 11 pts.wt. based on 100 pts.wt. total amount of the HPMC and the HPC.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To provide a new spin-labeled triglyceride compound useful as a new spin-labeling agent for spin labeling, which is an application of electron spin resonance to biomembrane, etc. CONSTITUTION:A spin-labeled triglyceride compound shown by formula I or formula II [R&lt;1&gt; is oleoyloxy or palmitoyloxy; R&lt;2&gt; is formula III (m)=0-10, (n)=1-5], e.g. 1,3-dioleoyl-(2)-12SLS-TG of formula IV. The compound of formula I is obtained by reacting a compound of the formula R&lt;2&gt;OH with a compound of formula V in the presence of a condensation agent. The compound of formula II is obtained by reacting a compound of the formula R&lt;2&gt;OH with formula VI in the presence of a condensation agent. In vivo distribution of triglyceride can be sequentially determined without giving stress to a living body in such a manner as a noninvasive analysis by the electron spin resonance measurement of the in vivo distribution of the compound of formula I or formula II administered to the living body.
PURPOSE:To provide the titled external agent containing an anionic water-soluble drug, by using an anionic water-soluble drug and a basic oil-soluble substance or its salt as active components. CONSTITUTION:A dermatic external agent having improved transcutaneous absorbability of an anionic water-soluble drug can be produced by compounding (A) an anionic water-soluble drug (which is solid at normal temperature and has a pKa of &lt;=4.5: e.g. an antiepileptic agent such as valproate sodium) and (B) a basic oil-soluble substance or its salt (having one or more dissociable basic groups in the molecule and soluble in oil: e.g. alkanolamine, its salt, quaternary ammonium, its salt, alkyldiamine, its salt, etc.) at a weight ratio of 1:0.05-100, preferably 1:0.1-80. The external agent can be applied in an arbitrary form contacting with skin for a moderate period (e.g. ointment, aerosol, lotion, poultice, tape, etc.).
The utility of Topo V&#39;s HhH motifs for modulating DNA binding properties of a DNA processing enzyme, such as Taq DNA polymerase or PfuDNA polymerase, is demonstrated. In one embodiment, an amino acid residue comprising one or more HhH domains derived from Topoisomerase V, linked to either the NH2-terminus or COOH-terminus of a Taq polymerase fragment, significantly broadens the processivity and/or salt concentration range of polymerase activity. The specific activities of the chimeric polymerases are not affected by added HhH motifs. Depending on the type of the construct, the thermal stability of chimeric polymerases increases or remains the same as that of Taq DNA polymerase or its Stoffel fragment. This invention further provides a method of increasing the salt tolerance of Taq polymerases. The methods of this invention may be applied to all pol A-type DNA polymerases, as well as to other DNA processing enzymes.
1. A compound of the formula:   or fumaric acid salt thereof. 2. The compound of claim 1, which is the compound of the formula:   3. A process for preparing a compound of the formula:   or fumaric acid salt thereof, which comprises (1) reacting a compound of the formula:   or its reactive derivative at the carboxy group or a salt thereof with a compound of the formula:   or its reactive derivative at the amino group or a salt thereof to give a compound of the formula:   or fumaric acid salt thereof, or (2) reacting a compound of the formula :   or a salt thereof other than fumaric acid salt thereof with fumaric acid to give a compound of the formula:   4. A pharmaceutical composition comprising a compound of claim 1 as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient. 5. A method for treating or preventing Tachykinin-mediated diseases which comprises administering an effective amount of a compound of claim 1 to a human being or animals. 6. A compound of claim 1 for use as a medicament. 7. Use of a compound of claim 1 for manufacture of a medicament for treating or preventing Tachykinin-mediated diseases. 8. A compound of the following general formula:   wherein R&lt;1&gt; is trihalo(lower)alkyl, R&lt;2&gt; is trihalo(lower)alkyl, R&lt;3&gt; is indolyl(lower)alkyl,   in which R&lt;5&gt; is hydrogen or lower alkoxycarbonyl, R&lt;6&gt; is hydrogen or lower alkanoyl, R&lt;7&gt; is hydrogen, lower alkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkoxy(lower)alkanoyl, cyclo(lower)alkylcarbonyl, aroyl or lower alkylsulfonyl, or its pharmaceutically acceptable salt.
A kind of hydrochloric piperphentonamine freeze-dried powder injection and their preparation methods. The injection is formed by freezing and drying with one portion of hydrochloric piperphentonam- ine, 2.5-30 portions of excipients and 400-600 portions of water for injection with pH=1.5-5.5. Excipient can be mannitol, dextran, lactosemilk sugar, saccharose, polyethylene glycol, poloxamer, Gly etc. It is preferred that the injection comprises one portion of hydrochloric piperphentonamine, 10 portions of excipients and 500 portions of water for injection with pH=2.0-3.0. The preparation method for the injection includes adding said hydrochloric piperphentonamine and excipient(s) into water, heating at 40-90 ?, being treated by ultrasonic wave, degerming, subpackage split charging,prefreezing,multistage&#39; s drying, packaging to obtain the production. Controlled glass bottle is used and the brown is preferred. The appearance, colour &amp; luster and solubility of the injection are excellent. It has good stability and long retention time. The uses of the injection in the preparation of medicament for heart failure and/or myocardial preservation.
An immediate and visible temporary cosmetic improvement in skin condition is obtained by a multi-stage exfoliation method having a visible end point and providing a margin of safety so that the user&#39;s skin is not significantly irritated if he or she ignores the end point and continues to carry out additional and unnecessary exfoliation steps. The preferred method involves repeatedly attaching transparent exfoliation sheets having a pressure sensitive adhesive to a selected part of the user&#39;s body and then removing each sheet by grasping one edge and pulling it across the rest of the sheet. A handle may be detachably adhered to each sheet for superior results. After each repetition the user inspects the sheet that has just been removed to monitor the amount of exfoliated tissue. When the amount of tissue on a sheet is discernibly less than that removed in the immediately previous repetition, the process is completed. Alternately, a user may compare each removed sheet with a prefabricated comparison sheet that shows a number of visually distinct regions representative of various amounts of exfoliated tissue and from this may recreate and set an individualized target end point that conforms to his or her specific desires and limitations for exfoliation. A set of precut exfoliation sheets shaped to fit a selected portion of the body may be sold in a kit that also includes a prefabricated comparison sheet, and a rod-like handle that can be attached to an edge of each of the sheets for application.
The present invention provides a preparation method for eight-treasure sugarless medicinal granules. Firstly, certain proportion of white atractylodes rhizome, angelica and hemlock parsley are processed by refluxing extraction with ethanol. Then the materials are decocted with water, and a semifinished product is obtained. Then pilose asiabell roots, tuckahoe, prepared rehmannia roots, licorice roots and radix paeoniae alba are added in the materials according to proportion. The materials are decocted with water, and an excipient is added in after the materials are filtered and concentrated. The products of eight-treasure sugarless medicinal granules are obtain after the materials are made into granules and dried. The present invention adopts an advanced reduced dynamic warm immersion technique, which ensures the maximal content of the 8 natural effective active components. The present invention has high medicine effect, doesn&#39;t comprise sugar, is suitable for diabetic patients, obesity patients, old patients and tooth decay patients to take, enlarges the using range of the original eight-treasure pills, doesn, t comprise pigment and preservative, and has convenient taking, transport and storage.